Supplementary Table 1 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Authors :: Ian D. Lewis
Dale Song
Pierre Fustier
Patrick Hagner
Anjan Thakurta
Jacqueline Russo
Chih-Jian Lih
P. Mickey Williams
Yandan Yang
Louis M. Staudt
George W. Wright
Pier Luigi Zinzani
Thomas E. Witzig
Gilles Salles
Francisco J. Hernandez-Ilizaliturri
David A. Eberhard
Pierre Brousset
Graham W. Slack
Randy D. Gascoyne
Nina Wagner-Johnston
Kim M. Linton
Simon Rule
Andrew Davies
Marek Trněný
Myron S. Czuczman
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Investigator's Choice (IC) Dosing Regimens

Tools